Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.
Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The leukemic stem cells (LSCs) are cells that self- renew and give rise to leukemia.
Eradication of LSC is required for cure. In chronic myelogenous leukemia (CML) LSCs are not
eradicated by imatinib (Gleevec) alone. Recent discovery by Dr. Shaoguang Li at University of
Massachusetts indicates that the LSCs can be targeted by a new drug zileuton (Chen et al.
Nature Genetics 2009; 41:783-792). Zileuton (approved for asthma) will be tested in a
combination with Gleevec. This combination has not been used previously to treat leukemia.
This is a Phase I study. The goal of this research is to evaluate the safety of the standard
anti-cancer drug imatinib and experimental drug zileuton.